Money flow has turned positive in Synergy Pharmaceuticals (SGYP +10.8%) albeit on modestly higher volume. Earlier today, would-be competitor Ardelyx (ARDX -36.7%) announced positive late-stage data on IBS-C candidate tenapanor but with a 14.6% rate of diarrhea, higher that Trulance's 5% (data from studies in chronic ideopathic constipation).
Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.